Your Best Stock
Stocks MET

MetLife MET

US equityMarket cap rank #261
$97.65
+$0.45 (+0.46%)
Market open · Sep 24, 1:10 pm ET
After hours $96.40 -0.83%
Open$97.33
Prev close$97.20
Day range$97.06 – $98.18
Volume1.26M
Market cap$62.05B
P/E (TTM)18.7
Dividend yield2.35%

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).

MET at a glance

MetLife (MET) is trading at $97.65, up 0.46% on the day. Its market value of $62.05B makes it the 261st largest of the 300 companies we follow.

The 52-week range is $66.41 to $100.93. Today's price is about 90% of the way from the low to the high. Holders are ahead 24.5% over twelve months, and up 16.1% across the last three months.

On the chart it holds above both the 50-day ($95.93) and 200-day ($82.39) moving averages; RSI is 53, and the last 30 sessions moved at roughly 19% annualized volatility.

For the quarter ended Jun 2026 it reported $18.88B in revenue, up 9.9% from a year earlier, with $779.00M of net profit (a 4.4% margin).

Valuation works out to 18.7 times trailing earnings, 11% above its five-year average of 16.8.

11 analysts follow the stock and the average call is "buy". The mean target, $106.09, sits 8.6% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

MetLife: the business

MetLife sells life insurance, annuities, employee benefits and retirement products, in the U.S. and abroad.

What tends to move it. Investment returns, interest rates and group benefit sales matter.

Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+0.5%
1 week
+0.4%
1 month
+1.5%
3 months
+16.1%
6 months
+41.7%
Year to date
+26.3%
1 year
+24.5%
Day range
$97.06$98.18
52-week range
$66.41$100.93

Technical signals

Full technicals →
Trend readStrong uptrend

6 bullish · 1 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average+1.0%Bullish
Price vs 50-day average+1.8%Bullish
Price vs 200-day average+18.5%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)53.2Bullish
MACD (12,26,9)0.40Bearish
Bollinger band position71%Bullish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Key statistics

Bid / Ask$97.63 / $97.67
Average price today$97.52
Volume1.26MAvg (90d) 3.52M
Turnover$123.17M
Turnover rate0.24%of shares outstanding
Volume ratio0.63vs. recent average pace
Day amplitude1.15%
Market cap$62.05B
Float market cap$51.88B
Shares outstanding531.23M
EPS (TTM)$4.71
P/E (TTM)18.71
P/B2.26
Book value / share$43.18
Earnings yield0.12%
Dividend (TTM)$2.30 / shareYield 2.35%
Net profit (TTM)$2.99B
Net assets$27.44B
30-day volatility19.0%annualized
Avg daily range (ATR)1.96%of price, 14 days
Max drawdown (1y)-17.5%-2.3% from 1y peak

Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.

How MET ranks on BeStock

Market value#261 of 300
P/E (cheapest = 1)#99 of 283
Dividend yield#93 of 244
Closeness to 52-week high#19 of 300
Dollar volume today#225 of 300

Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.

Latest reported quarter: Q2, ended Jun 2026

Revenue$18.88B+9.9% YoY
Net profit$779.00M+6.0% YoY
Diluted EPS$1.09+5.8% YoY
Free cash flow$2.23B+1.9% YoY
Operating cash flow$2.23B

Revenue, last 8 quarters

$18.3BSep '24$18.6BDec '24$18.3BMar '25$17.2BJun '25$16.9BSep '25$23.3BDec '25$18.6BMar '26$18.9BJun '26

Net profit, last 8 quarters

$1.3BSep '24$1.3BDec '24$950.0MMar '25$735.0MJun '25$902.0MSep '25$816.0MDec '25$1.2BMar '26$779.0MJun '26

Profitability & balance sheet

Net margin4.4%
Return on equity12.5%
Return on assets0.5%
Liabilities / assets96.3%
Total debt$21.35B
Free cash flow / sales20.0%

Where the revenue comes from

Quarter 2026/Q2

By business line

  • Group Benefits$6.87B 33.7%
  • Retirement and Income Solutions (RIS)$3.99B 19.5%
  • Asia$3.07B 15.1%
  • Latin America$2.49B 12.2%
  • Corporate & Other$1.47B 7.2%
  • Unit-linked investment income$998.00M 4.9%
  • Europe, the Middle East, and Africa (EMEA)$873.00M 4.3%
  • Reinsurance activity$331.00M 1.6%
  • MetLife Investment Management, the Company’s institutional asset management business (MIM)$319.00M 1.6%
Average move on report day±3.0%last 16 reports
Closed higher4 of 1625% of the time
Best reaction+3.8%
Worst reaction-7.8%

Stock move on the day after each report

-5.7%2024/Q3-1.6%2024/Q4+0.5%2025/Q1-2.8%2025/Q2-3.4%2025/Q3-3.4%2025/Q4-1.7%2026/Q1+3.8%2026/Q2

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Valuation

Multiples measured against the stock's own five-year history

Valuation detail →
Price / earnings18.6x
CheapRich

Above its usual level · 64th percentile, 5-year average 16.8x

#1435 of 2977 stocks by PE (1 = cheapest)

Price / book2.2x
CheapRich

Near the top of its 5-year range · 94th percentile, 5-year average 1.6x

#3061 of 5304 stocks by PB (1 = cheapest)

Price / sales0.8x
CheapRich

Above its usual level · 74th percentile, 5-year average 0.7x

#1284 of 5143 stocks by PS (1 = cheapest)

P/E over five years

-205x-76x52x180xSep '21Mar '24Sep '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$84.00
Price vs. fair value+16.3%Trading above the estimate
Star rating★★☆☆☆
UncertaintyMedium

Analyst view

All ratings →
ConsensusBuy
Analysts11
Average target$106.09+8.6% vs. price
  • Buy 91%
  • Hold 9%
Low $90.00Now $97.65Avg $106.09High $119.00

Latest rating actions

  • 24 Aug 2026Morgan StanleyBUY · PT $111.00
  • 19 Aug 2026Wells FargoBUY · PT $109.00
  • 11 Aug 2026Mizuho SecuritiesBUY · PT $112.00
  • 11 Aug 2026J.P. MorganBUY · PT $108.00
  • 11 Aug 2026KBWBUY · PT $108.00

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Ownership detail →
Institutional ownership94.2%-0.03 pts vs. prior quarter
Institutions holding1,690-3 vs. prior quarter
Insider trades (recent)14 buys / 4 sellsNet buying
Short interest1.87% of floatDays to cover 4.0 · as of 31 Aug 2026
Short-sale volume share26.7%5-day average of daily volume

Short-sale volume as % of daily volume

18%24%30%36%Aug '26Sep '26Sep '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$32.48M (5 inflow days, 15 outflow days).

Dividends

Dividend yield (TTM)2.35%
Last dividend$0.59Ex-date 4 Aug 2026
Next-to-last$0.59
Payments on file40

Dividends paid per share, by year

1.6620181.7420191.8220201.9020211.9820222.0620232.1620242.252025

Across the full calendar years shown, the annual payout grew by roughly 4.4% a year.

Latest headlines

More news →
  • Hailanxin (300065.SZ): No overseas orders for underwater data centers have met disclosure standards.Gelonghui Finance · 8 Sep 2026
  • Top U.S. Stock Performers This Week | Roivant Sciences surged more than 17% this week as Phase II data for mosliciguat, developed by its subsidiary, met endpoints in treating PH-ILD; Cloudflare rose nearly 12%, indirectly benefiting as an edge computing pMarket news · 11 Sep 2026
  • US August PPI month-on-month growth met expectations, while year-on-year growth slightly exceeded forecasts.Global Market Briefing · 10 Sep 2026
  • Court Closes Light S.A. Judicial Reorganization After Plan Obligations MetTipRanks · 10 Sep 2026
  • The new iPhone launch met expectations and drove an increase in ASP, but the outlook for the iPhone remains uncertain.CSOP · 10 Sep 2026
  • Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the interim analysis of its Phase III clinical trial of Yizekang® (LunKang Yilong Tuodan Kang, BL‑B01D1/iza‑bren) for the treatment of locally advanced, recurrent, or metastatic HR+HER2‑negative breast cancer, which has met the primary endpoint.SZSI · 26 Aug 2026

MET stock: common questions

How is MetLife stock doing today?

$97.65 is the latest print for MET, a move of +0.46% against yesterday's close of $97.20. Today's low and high so far: $97.06 and $98.18.

How large is MetLife by market value?

Equity value comes to $62.05B at the current price. By that measure it is number 261 of the 300 names in our coverage.

How is MetLife valued against its profits?

Buyers pay 18.7 times the last twelve months of profit (EPS $4.71). Averaged over five years the multiple has been 16.8, and today's level ranks in the 64th percentile of its own history.

How far is MET from its yearly high?

The year's floor is $66.41 and the ceiling $100.93. Shares are 3.2% away from that ceiling.

Are there dividends on MetLife shares?

It does. Payouts over the past twelve months work out to a 2.35% yield; the latest ex-dividend date was August 4, 2026.

Do Wall Street analysts like MET?

Of 11 analysts, 91% say buy, 9% hold and 0% sell. Price targets average $106.09, with the most cautious at $90.00 and the most optimistic at $119.00.

How does MetLife make money?

MetLife sells life insurance, annuities, employee benefits and retirement products, in the U.S. and abroad.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Scroll to Top